摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-phenyl-2-oxo-3H-1,3-oxazol-5-yl)benzenesulfonamide | 13342-74-0

中文名称
——
中文别名
——
英文名称
4-(4-phenyl-2-oxo-3H-1,3-oxazol-5-yl)benzenesulfonamide
英文别名
4-(2-oxo-4-phenyl-2,3-dihydro-oxazol-5-yl)-benzenesulfonamide;4-(2-oxo-4-phenyl-2,3-dihydro-1,3-oxazol-5-yl)benzenesulfonamide;4-Phenyl-5--oxazol-2-on;4-(2-oxo-4-phenyl-3H-1,3-oxazol-5-yl)benzenesulfonamide
4-(4-phenyl-2-oxo-3H-1,3-oxazol-5-yl)benzenesulfonamide化学式
CAS
13342-74-0
化学式
C15H12N2O4S
mdl
——
分子量
316.337
InChiKey
XQVSFQBKZWJYMT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    107
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    4-(4-phenyl-2-oxo-3H-1,3-oxazol-5-yl)benzenesulfonyl chlorideammonium hydroxide盐酸 作用下, 以 为溶剂, 反应 1.0h, 以58%的产率得到4-(4-phenyl-2-oxo-3H-1,3-oxazol-5-yl)benzenesulfonamide
    参考文献:
    名称:
    Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors
    摘要:
    A series of 3-unsubstituted/substituted-4,5-diphenyl-2-oxo-3H-1,3-oxazole derivatives were prepared as selective cyclooxygenase-2 (COX-2) inhibitors. Among the synthesized compounds, 4-(4-phenyl-3-methyl-2-oxo-3H-1,3-oxazol-5-yl)benzensulfonamide (compound 6) showed selective COX-2 inhibition with a selectivity index of >50 (IC50COX-1 = >100 mu M, IC50COX-2 = 2 mu m) in purified enzyme (PE) assay. Compound 6 also exhibited selective COX-2 inhibition in human whole blood assay. Molecular docking studies showed that 6 can be docked into the COX-2 binding site thus providing the molecular basis for its activity. (C) 2008 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2008.10.039
点击查看最新优质反应信息

文献信息

  • 4-Aroylbenzils and related compounds
    作者:Hilton Greenberg、Theodorus Van Es、O. G. Backeberg
    DOI:10.1021/jo01285a006
    日期:1967.10
  • COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
    申请人:Pharmacia Corporation
    公开号:EP1682143A2
    公开(公告)日:2006-07-26
  • [EN] COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA<br/>[FR] ASSOCIATION DE L'INHIBITEUR DE HSP90 ET DE L'INHIBITEUR DE LA PHOPHODIESTERASE DESTINEE A TRAITER OU PREVENIR LA NEOPLASIE
    申请人:PHARMACIA CORP
    公开号:WO2005041879A2
    公开(公告)日:2005-05-12
    A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising an Hsp90 inhibitor and a phosphodiesterase inhibitor, and optionally a Cox-2 inhibitor.
  • [EN] TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR<br/>[FR] TRAITEMENT OU PREVENTION DE LA NEOPLASIE A L'AIDE D'UN INHIBITEUR DE LA PROTEINE HSP90
    申请人:PHARMACIA CORP
    公开号:WO2005044194A2
    公开(公告)日:2005-05-19
    A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of an Hsp90 inhibitor, or of a combination comprising an Hsp90 inhibitor and a Cox-2 inhibitor.
查看更多